What is Zacks Research's Forecast for Amarin Q2 Earnings?

Key Points

• Zacks Research has cut Amarin's Q2 2025 earnings estimate from ($0.60) to ($0.79) per share.
• Amarin reported earnings of ($0.03) per share for the latest quarter, exceeding expectations of ($0.60) by $0.57.
• The stock has recently experienced target price changes, with Goldman Sachs raising it to $12.00 while maintaining a "sell" rating.

Amarin Corporation PLC (NASDAQ:AMRN - Free Report) - Equities research analysts at Zacks Research dropped their Q2 2025 EPS estimates for Amarin in a research report issued on Tuesday, July 29th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of ($0.79) for the quarter, down from their previous forecast of ($0.60). The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.79) EPS, FY2026 earnings at ($1.93) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at $0.26 EPS and FY2027 earnings at ($0.91) EPS.

AMRN has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Amarin from a "hold" rating to a "buy" rating in a research report on Saturday. The Goldman Sachs Group lifted their target price on shares of Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a research report on Wednesday, June 25th.

Amarin Price Performance

AMRN traded up $0.64 during midday trading on Thursday, reaching $15.16. 88,516 shares of the company's stock were exchanged, compared to its average volume of 81,295. The stock has a market capitalization of $313.96 million, a PE ratio of -4.13 and a beta of 0.84. The business's 50-day moving average price is $14.46 and its 200 day moving average price is $11.75. Amarin has a 1-year low of $7.08 and a 1-year high of $17.49.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its earnings results on Wednesday, July 30th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.63. The company had revenue of $72.74 million during the quarter, compared to analysts' expectations of $45.45 million. Amarin had a negative net margin of 47.22% and a negative return on equity of 21.18%.

Institutional Investors Weigh In On Amarin

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Kornitzer Capital Management Inc. KS grew its holdings in shares of Amarin by 4.0% during the first quarter. Kornitzer Capital Management Inc. KS now owns 88,200 shares of the biopharmaceutical company's stock worth $40,000 after buying an additional 3,400 shares in the last quarter. LCM Capital Management Inc grew its holdings in shares of Amarin by 2.4% during the first quarter. LCM Capital Management Inc now owns 858,259 shares of the biopharmaceutical company's stock worth $385,000 after buying an additional 20,000 shares in the last quarter. LPL Financial LLC grew its holdings in shares of Amarin by 26.0% during the fourth quarter. LPL Financial LLC now owns 153,020 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 31,555 shares in the last quarter. Waterfront Wealth Inc. grew its holdings in shares of Amarin by 1.3% during the first quarter. Waterfront Wealth Inc. now owns 2,514,615 shares of the biopharmaceutical company's stock worth $1,127,000 after buying an additional 32,849 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Amarin by 3.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company's stock worth $650,000 after buying an additional 39,452 shares in the last quarter. 22.25% of the stock is currently owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.